myriad
genetics
files
fiscal
year
proxy
statement
implements
corporate
governance
changes
support
stakeholder
interests
salt
lake
city
globe
newswire
myriad
genetics
nasdaq
mygn
global
leader
molecular
diagnostics
precision
medicine
announced
today
company
filed
fiscal
year
proxy
statement
made
significant
changes
board
structure
executive
compensation
corporate
governance
policies
better
serve
key
company
stakeholders
myriad
executed
significant
effort
time
chair
improve
corporate
governance
reflect
shareholder
interests
continuing
mission
improve
transform
lives
said
louise
phanstiel
chair
board
directors
myriad
genetics
end
year
board
consist
new
members
bring
deep
healthcare
technology
expertise
spanning
payer
markets
product
development
information
technology
business
management
intensifying
focus
corporate
governance
transparency
myriad
positioned
advance
leadership
healthcare
board
membership
since
fall
myriad
added
six
new
members
board
directors
announced
retirement
three
board
members
new
board
members
include
lee
newcomer
colleen
reitan
daniel
skovronsky
daniel
spiegelman
rashmi
kumar
paul
diaz
retiring
board
directors
following
annual
meeting
december
john
henderson
lawrence
best
walter
gilbert
march
louise
phanstiel
assumed
role
board
chair
new
board
structure
designed
combine
continuity
tenured
directors
new
perspectives
recently
added
members
broad
experience
managed
care
health
technology
financial
oversight
addition
myriad
enacting
new
policies
reflect
industry
best
practices
including
moving
plurality
voting
majority
voting
directors
implementing
retirement
process
directors
age
expanding
scope
audit
finance
committee
redefining
strategic
committee
new
research
product
innovation
committee
enhancing
board
diversity
board
members
reflecting
diverse
backgrounds
related
executive
compensation
changes
myriad
also
making
multiple
changes
compensation
policies
match
business
performance
compensation
changes
include
business
objectives
vice
presidents
based
company
financial
performance
bonus
payout
tied
achievement
revenue
operating
income
targets
equity
granted
incentive
compensation
consist
performance
shares
number
shares
tied
company
performance
earnings
per
share
relative
total
shareholder
return
reducing
management
payouts
moving
double
trigger
system
equity
vesting
elimination
future
cash
incentive
programs
change
fiscal
year
end
order
better
align
general
industry
standards
financial
reporting
facilitate
comparison
companies
myriad
adjust
fiscal
year
end
june
december
myriad
file
annual
report
form
transition
period
july
december
fiscal
year
run
january
end
calendar
year
december
take
decisive
actions
enhance
governance
drive
sustainable
profitable
growth
remain
focused
mission
improve
transform
lives
unlocking
power
genetics
paul
diaz
president
ceo
myriad
genetics
continue
transform
business
listening
responding
needs
stakeholders
creating
new
commercial
capabilties
delivering
new
levels
value
innovation
service
myriad
genetics
myriad
genetics
leading
personalized
medicine
company
dedicated
trusted
advisor
transforming
patient
lives
worldwide
pioneering
molecular
diagnostics
myriad
discovers
commercializes
molecular
diagnostic
tests
determine
risk
developing
disease
accurately
diagnose
disease
assess
risk
disease
progression
guide
treatment
decisions
across
six
major
medical
specialties
molecular
diagnostics
significantly
improve
patient
care
lower
healthcare
costs
information
visit
company
website
myriad
myriad
logo
bart
bracanalysis
colaris
colaris
ap
mypath
myrisk
myriad
myrisk
myrisk
hereditary
cancer
mychoice
myplan
bracanalysis
cdx
tumor
bracanalysis
cdx
mychoice
cdx
vectra
prequel
foresight
genesight
riskscore
prolaris
trademarks
registered
trademarks
myriad
genetics
wholly
owned
subsidiaries
united
states
foreign
countries
safe
harbor
statement
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
including
statements
related
company
board
consisting
new
members
end
year
company
advancing
leadership
healthcare
industry
retirement
board
directors
following
annual
meeting
december
john
henderson
lawrence
best
walter
gilbert
planned
new
policies
governance
changes
listed
company
adjusting
fiscal
year
end
june
company
continuing
transform
business
company
delivering
new
levels
value
innovation
service
excellence
company
strategic
directives
caption
myriad
genetics
statements
based
management
current
expectations
future
events
subject
number
risks
uncertainties
could
cause
actual
results
differ
materially
adversely
set
forth
implied
statements
risks
uncertainties
include
limited
uncertainties
associated
including
possible
effects
operations
demand
products
services
ability
efficiently
flexibly
manage
business
amid
uncertainties
related
risk
sales
profit
margins
molecular
diagnostic
tests
pharmaceutical
clinical
services
may
decline
risks
related
ability
transition
existing
product
portfolio
new
tests
including
unexpected
costs
delays
risks
related
decisions
changes
governmental
private
insurers
reimbursement
levels
tests
ability
obtain
reimbursement
new
tests
comparable
levels
existing
tests
risks
related
increased
competition
development
new
competing
tests
services
risk
may
unable
develop
achieve
commercial
success
additional
molecular
diagnostic
tests
pharmaceutical
clinical
services
timely
manner
risk
may
successfully
develop
new
markets
molecular
diagnostic
tests
pharmaceutical
clinical
services
including
ability
successfully
generate
revenue
outside
united
states
risk
licenses
technology
underlying
molecular
diagnostic
tests
pharmaceutical
clinical
services
future
tests
services
terminated
maintained
satisfactory
terms
risks
related
delays
problems
operating
laboratory
testing
facilities
healthcare
clinic
risks
related
public
concern
genetic
testing
general
tests
particular
risks
related
regulatory
requirements
enforcement
united
states
foreign
countries
changes
structure
healthcare
system
healthcare
payment
systems
risks
related
ability
obtain
new
corporate
collaborations
licenses
acquire
new
technologies
businesses
satisfactory
terms
risks
related
ability
successfully
integrate
derive
benefits
technologies
businesses
license
acquire
risks
related
projections
business
results
operations
financial
condition
risks
related
potential
market
opportunity
products
services
risk
licensors
may
unable
protect
third
parties
infringe
proprietary
technologies
underlying
tests
risk
claims
challenges
validity
patents
intellectual
property
risks
related
changes
intellectual
property
laws
covering
molecular
diagnostic
tests
pharmaceutical
clinical
services
patents
enforcement
united
states
foreign
countries
supreme
court
decisions
mayo
collab
servs
prometheus
ass
n
molecular
pathology
myriad
genetics
alice
cls
bank
int
l
risks
new
changing
competitive
technologies
regulations
united
states
internationally
risk
may
unable
comply
financial
operating
covenants
credit
lending
agreements
risk
unable
pay
due
amounts
due
credit
lending
agreements
factors
discussed
heading
risk
factors
contained
item
recent
annual
report
form
fiscal
year
ended
june
filed
securities
exchange
commission
well
updates
risk
factors
filed
time
time
quarterly
reports
form
current
reports
form
information
press
release
date
release
myriad
undertakes
duty
update
information
unless
required
law
